- Home
- CBOE vs PODD Comparison
CBOE vs PODD Comparison
Compare CBOE & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBOE | PODD |
|---|---|---|
| Founded | 1973 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 22.1B |
| IPO Year | 2010 | 2007 |
Fundamental Metrics
Financial Performance| Metric | CBOE | PODD |
|---|---|---|
| Price | $253.22 | $295.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $244.64 | ★ $359.00 |
| AVG Volume (30 Days) | 662.9K | ★ 791.4K |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 26.68 | N/A |
| EPS | ★ 9.30 | 3.45 |
| Revenue | ★ $4,617,800,000.00 | $2,521,800,000.00 |
| Revenue This Year | N/A | $32.55 |
| Revenue Next Year | $5.52 | $20.39 |
| P/E Ratio | ★ $27.21 | $85.69 |
| Revenue Growth | 16.74 | ★ 27.11 |
| 52 Week Low | $187.30 | $230.05 |
| 52 Week High | $262.98 | $354.88 |
Technical Indicators
Market Signals| Indicator | CBOE | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 38.33 |
| Support Level | $247.68 | $290.98 |
| Resistance Level | $257.23 | $306.04 |
| Average True Range (ATR) | 4.06 | 9.59 |
| MACD | -1.00 | -3.01 |
| Stochastic Oscillator | 42.43 | 9.03 |
Price Performance
Historical ComparisonAbout CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.